Unknown

Dataset Information

0

The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status.


ABSTRACT: Inter- and intratumoral heterogeneity is a hallmark of glioblastoma (GBM) that facilitates recurrence, treatment resistance, and worse prognosis. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a significant prognostic marker for Temozolomide (TMZ) resistance in GBM patients. YKL-40 is a molecular marker for the mesenchymal subtype of GBMs and is responsible for TMZ resistance. However, underlying mechanisms by which MGMT epigenetics impacts patient outcomes and the function of YKL-40 are not fully determined. Herein, we performed in vitro and in vivo experiments, six human IDH1/2 wild-type glioblastoma stem-like cells (GSCs) were established and studied to further determine a potential interaction of YKL-40 and MGMT promoter methylation. We demonstrated that YKL-40 functioned differently in human IDH1/2 wild-type GSCs. In MGMT promoter-methylated (MGMT-m) GSCs, it acted as a tumor suppressor gene. On the other hand, in MGMT promoter-unmethylated (MGMT-um) GSCs, it promoted tumorigenesis. Notably, the reason that YKL-40 played different roles in GSCs could not be interpreted by the molecular classification of each GSCs, but is a function of MGMT promoter methylation status and involves the RAS-MEK-ERK pathway. YKL-40 mediated TMZ sensitivity by activating DNA damage responses (DDRs) in MGMT-m GSCs, and it mediated resistance to TMZ by inhibiting DDRs in MGMT-um GSCs. Our report demonstrated that MGMT promoter methylation status might influence a gene's function in human cancer. Moreover, our data also highlight the point that gene function should be investigated not only according to the molecular tumor classification, but also the epigenetic signature.

SUBMITTER: Chen WJ 

PROVIDER: S-EPMC7441403 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status.

Chen Wei-Jun WJ   Zhang Xiang X   Han Hua H   Lv Jian-Nan JN   Kang En-Ming EM   Zhang Yu-Lian YL   Liu Wei-Ping WP   He Xiao-Sheng XS   Wang James J   Wang Gui-Huai GH   Yu Yan-Bing YB   Zhang Wei W  

Cell death & disease 20200821 8


Inter- and intratumoral heterogeneity is a hallmark of glioblastoma (GBM) that facilitates recurrence, treatment resistance, and worse prognosis. O<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a significant prognostic marker for Temozolomide (TMZ) resistance in GBM patients. YKL-40 is a molecular marker for the mesenchymal subtype of GBMs and is responsible for TMZ resistance. However, underlying mechanisms by which MGMT epigenetics impacts patient outcomes and  ...[more]

Similar Datasets

2023-07-01 | GSE153794 | GEO
| S-EPMC3792931 | biostudies-literature
| S-EPMC2790867 | biostudies-literature
| S-EPMC3083166 | biostudies-literature
| S-EPMC6089138 | biostudies-literature
| S-EPMC4161852 | biostudies-literature
| S-EPMC9354172 | biostudies-literature
| S-EPMC5817966 | biostudies-literature
| S-EPMC6783410 | biostudies-literature
| S-EPMC3890309 | biostudies-literature